TY - JOUR
T1 - Hydroximic Acid Derivatives
T2 - Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
AU - Crul, Tim
AU - Toth, Noemi
AU - Piotto, Stefano
AU - Literati-Nagy, Peter
AU - Tory, Kalman
AU - Haldimann, Pierre
AU - Kalmar, Bernadett
AU - Greensmith, Linda
AU - Torok, Zsolt
AU - Balogh, Gabor
AU - Gombos, Imre
AU - Campana, Federica
AU - Concilio, Simona
AU - Gallyas, Ferene
AU - Nagy, Gabor
AU - Berente, Zoltan
AU - Gungor, Burcin
AU - Peter, Maria
AU - Glatz, Attila
AU - Hunya, Akos
AU - Literati-Nagy, Zsuzsanna
AU - Vigh, Laszlo
AU - Hoogstra-Berends, Femke
AU - Heeres, Andre
AU - Kuipers, Irma
AU - Loen, Lizette
AU - Seerden, Jean-Paul
AU - Zhang, Deli
AU - Meijering, Roelien A. M.
AU - Henning, Robert H.
AU - Brundel, Bianca J. J. M.
AU - Kampinga, Harm H.
AU - Koranyi, Laszlo
AU - Szilvassy, Zoltan
AU - Mandl, Jozsef
AU - Sumegi, Balazs
AU - Febbraio, Mark A.
AU - Horvath, Ibolya
AU - Hooper, Philip L.
AU - Vigh, Laszlo
PY - 2013/1
Y1 - 2013/1
N2 - According to the "membrane sensor" hypothesis, the membrane's physical properties and microdomain organization play an initiating role in the heat shock response. Clinical conditions such as cancer, diabetes and neurodegenerative diseases are all coupled with specific changes in the physical state and lipid composition of cellular membranes and characterized by altered heat shock protein levels in cells suggesting that these "membrane defects" can cause suboptimal hsp-gene expression. Such observations provide a new rationale for the introduction of novel, heat shock protein modulating drug candidates. Intercalating compounds can be used to alter membrane properties and by doing so normalize dysregulated expression of heat shock proteins, resulting in a beneficial therapeutic effect for reversing the pathological impact of disease. The membrane (and lipid) interacting hydroximic acid (HA) derivatives discussed in this review physiologically restore the heat shock protein stress response, creating a new class of "membrane-lipid therapy" pharmaceuticals. The diseases that HA derivatives potentially target are diverse and include, among others, insulin resistance and diabetes, neuropathy, atrial fibrillation, and amyotrophic lateral sclerosis. At a molecular level HA derivatives are broad spectrum, multi-target compounds as they fluidize yet stabilize membranes and remodel their lipid rafts while otherwise acting as PARP inhibitors. The HA derivatives have the potential to ameliorate disparate conditions, whether of acute or chronic nature. Many of these diseases presently are either untreatable or inadequately treated with currently available pharmaceuticals. Ultimately, the HA derivatives promise to play a major role in future pharmacotherapy.
AB - According to the "membrane sensor" hypothesis, the membrane's physical properties and microdomain organization play an initiating role in the heat shock response. Clinical conditions such as cancer, diabetes and neurodegenerative diseases are all coupled with specific changes in the physical state and lipid composition of cellular membranes and characterized by altered heat shock protein levels in cells suggesting that these "membrane defects" can cause suboptimal hsp-gene expression. Such observations provide a new rationale for the introduction of novel, heat shock protein modulating drug candidates. Intercalating compounds can be used to alter membrane properties and by doing so normalize dysregulated expression of heat shock proteins, resulting in a beneficial therapeutic effect for reversing the pathological impact of disease. The membrane (and lipid) interacting hydroximic acid (HA) derivatives discussed in this review physiologically restore the heat shock protein stress response, creating a new class of "membrane-lipid therapy" pharmaceuticals. The diseases that HA derivatives potentially target are diverse and include, among others, insulin resistance and diabetes, neuropathy, atrial fibrillation, and amyotrophic lateral sclerosis. At a molecular level HA derivatives are broad spectrum, multi-target compounds as they fluidize yet stabilize membranes and remodel their lipid rafts while otherwise acting as PARP inhibitors. The HA derivatives have the potential to ameliorate disparate conditions, whether of acute or chronic nature. Many of these diseases presently are either untreatable or inadequately treated with currently available pharmaceuticals. Ultimately, the HA derivatives promise to play a major role in future pharmacotherapy.
KW - Stress response
KW - drug development
KW - hydroximic acid derivatives
KW - BGP-15
KW - geranylgeranylacetone derivatives
KW - insulin sensitizer
KW - neuroprotection
KW - atrial fibrillation
KW - HEAT-SHOCK-PROTEIN
KW - AMYOTROPHIC-LATERAL-SCLEROSIS
KW - APOPTOSIS-INDUCING FACTOR
KW - BETA-AMYLOID PEPTIDE
KW - NF-KAPPA-B
KW - POLY(ADP-RIBOSE) POLYMERASE-1 PARP-1
KW - ACETAMINOPHEN-INDUCED HEPATOTOXICITY
KW - TRANSGENIC CAENORHABDITIS-ELEGANS
KW - POSTOPERATIVE ATRIAL-FIBRILLATION
KW - OBSTRUCTIVE PULMONARY-DISEASE
M3 - Article
SN - 1381-6128
VL - 19
SP - 309
EP - 346
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 3
ER -